AVLN Avalyn Pharma Inc.

Fundamentals / CIK 0001540171 / USD

Avalyn Pharma Inc. reported $399.3M in total assets through September 30, 2026 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open AVLN in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

No annual income statement rows are available in SEC EDGAR CompanyFacts for AVLN.

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Research & Development $25.49M $24.73M $22.89M $22.09M $17.88M $15.32M
Total Operating Expenses $33.09M $31.29M $27.91M $25.32M $21.78M $18.72M
Operating Income -$33.09M -$31.29M -$27.91M -$25.32M -$21.78M -$18.72M
EBITDA -$32.99M -$31.18M -$27.85M -$25.31M -$21.77M -$18.71M
Interest Income $3.76M $2.70M $1.12M $1.79M $1.63M $1.25M
Interest Expense $277K $272K $98K $1.0K $0 $0
Income Tax Expense $0 $0 $0 $0 $0 $0
Net Income -$29.66M -$28.93M -$26.87M -$23.58M -$20.19M -$17.50M
Basic EPS -$0.67 -$0.98 -$21.83 -$20.34 -$17.63 -$63.24
Diluted EPS -$0.67 -$0.98 -$21.83 -$20.34 -$17.63 -$63.24
Basic Shares Outstanding 44.4M 29.7M 1.2M 1.2M 1.1M 276.8K
Diluted Shares Outstanding 44.4M 29.7M 1.2M 1.2M 1.1M 276.8K

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

No annual balance sheet rows are available in SEC EDGAR CompanyFacts for AVLN.

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2026-03-31 2025-12-31
Cash & Cash Equivalents $145.4M $264.2M $92.31M $52.31M
Short-Term Investments $182.0M $88.23M $30.82M $86.04M
Cash & Short-Term Investments $327.5M $352.4M $123.1M $138.4M
Total Current Assets $333.7M $358.0M $130.0M $143.6M
Property, Plant & Equipment, Net $1.17M $1.21M $1.26M $792K
Long-Term Investments $59.14M $61.10M -- $0
Other Non-Current Assets $3.32M $3.01M $3.00M $3.00M
Total Non-Current Assets $65.59M $67.46M $5.68M $5.32M
Total Assets $399.3M $425.4M $135.7M $148.9M
Accounts Payable $2.70M $2.65M $3.15M $3.76M
Total Current Liabilities $12.96M $10.81M $11.79M $14.09M
Long-Term Debt $14.82M $14.80M $14.81M $0
Total Non-Current Liabilities $16.09M $16.29M $15.90M $1.23M
Total Liabilities $29.05M $27.10M $27.69M $15.32M
Total Debt (incl. Leases) $16.93M $17.11M $16.41M $1.67M
Common Stock $67K $67K $24K $24K
Retained Earnings -$350.8M -$321.2M -$292.2M -$265.4M
Accumulated Other Comp. Income -$994K -$95K $12K $134K
Total Stockholders' Equity $370.2M $398.3M -$264.2M -$238.7M
Total Equity $370.2M $398.3M -$264.2M -$238.7M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

No annual cash flow statement rows are available in SEC EDGAR CompanyFacts for AVLN.

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Net Income -$29.66M -$28.93M -$26.87M -$23.58M -$20.19M -$17.50M
Depreciation & Amortization $104K $110K $63K $9.0K $9.0K $10K
Stock-Based Compensation $3.10M $2.79M $1.19M $725K $1.13M $543K
Change in Payables $146K -$93K -$1.11M $2.58M -$364K -$1.01M
Operating Cash Flow -$26.27M -$26.08M -$29.89M -$17.31M -$20.70M -$19.27M
Capital Expenditure -$72K -$269K -$318K -$84K $0 -$8.0K
Free Cash Flow -$26.34M -$26.34M -$30.21M -$17.39M -$20.70M -$19.28M
Purchases of Investments -$106.2M -$134.8M $0 -$42.24M -$64.19M -$2.87M
Investing Cash Flow -$91.77M -$118.7M $55.02M -$26.32M -$36.69M $24.12M
Common Stock Issued -- -- $50.00M -- -- --
Financing Cash Flow -$733K $316.7M $14.86M $9.90M $89.88M $0

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

No annual ratios & growth rows are available in SEC EDGAR CompanyFacts for AVLN.

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Current Ratio 25.76x 33.12x 11.03x -- -- --
Quick Ratio 25.28x 32.60x 10.45x -- -- --
Debt to Equity 0.05x 0.04x -- -- -- --
Source: SEC EDGAR CompanyFacts (CIK 0001540171) · from March 31, 2025 Data through September 30, 2026 · synced Nov 20, 2026, 05:27 UTC · Open in terminal